Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18498144 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1FAAHS1PR1S1PR5 | |
| SCHEMBL18498200 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1FAAHS1PR1S1PR5 | |
| SCHEMBL6738629 | 0.85 | L3MBTL1 (0.52) | TSHRL3MBTL1 | |
| SCHEMBL6739080 | 0.85 | FAAH (0.40) | KDM4EALDH1A1FAAHHSD11B1S1PR1 | |
| SCHEMBL6737613 | 0.84 | FAAH (0.66) | KDM4EFAAHMAPT | |
| SCHEMBL6733582 | 0.83 | CYP3A4 (0.46) | KDM4EALDH1A1FAAHHSD11B1S1PR1 | |
| SCHEMBL1895069 | 0.82 | CYP2D6 (0.54) | ALDH1A1HSD11B1S1PR1S1PR5MEN1 | |
| SCHEMBL6318888 | 0.82 | S1PR5 (0.53) | ALDH1A1FAAHHSD11B1S1PR1S1PR5 | |
| SCHEMBL9520601 | 0.81 | FAAH (0.62) | KDM4EALDH1A1FAAHTSHRSMN1; SMN2 | |
| SCHEMBL9520911 | 0.80 | MAPT (0.63) | KDM4EALDH1A1FAAHTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| WO-2000077000-A9 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | WO | disclosed |
| EP-1192157-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077000-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | KDM4E 4541/4885ALDH1A1 790/4885FAAH 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.